Physician profile
John Vanloock
NPI 1366471286
$1,386,069.99
in general payments reported to CMS, 2019-2025
24 companies · $268K in 2025
The $268K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198K · 2020: $113K · 2021: $207K · 2022: $240K · 2023: $211K · 2024: $149K · 2025: $268K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $572K · Travel and Lodging: $34K · Food and Beverage: $12K · Consulting Fee: $10K · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $571,563.00 |
| Travel and Lodging | $33,714.65 |
| Food and Beverage | $12,446.51 |
| Consulting Fee | $10,028.00 |
| Education | $293.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $472,699.39 | 2019-2025 | |
| Abbvie INC. | $387,194.11 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $290,349.81 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $125,061.13 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Janssen Scientific Affairs, LLC | $106,965.37 | 2019-2025 | Tremfya |
| Fresenius Kabi USA, LLC | $2,033.83 | 2023 | Idacio |
| Incyte Corporation | $426.92 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $393.31 | 2022-2025 | |
| Dermavant Sciences, INC. | $216.71 | 2023-2024 | Vtama |
| Pfizer INC. | $139.14 | 2019-2022 | |
| Inspire Medical Systems, INC. | $120.62 | 2025 | Inspire |
| Ucb, INC. | $88.02 | 2020-2025 | Bimzelx |
| Lilly USA, LLC | $64.54 | 2020-2024 | Ebglyss |
| Leo Pharma INC. | $60.22 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $55.71 | 2023-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $51.72 | 2023-2024 | Tolak |
| Organon LLC | $27.36 | 2025 | Vtama, Nexplanon |
| Amgen INC. | $27.21 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $26.05 | 2023 | Dupixent |
| Galderma Laboratories, L.P. | $19.18 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $15.39 | 2024 | |
| Sanofi US Services INC. | $14.08 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.17 | 2023 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vanloock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.